allodynia glp 1 GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation Benefit-Risk Assessment of GLP-1 Receptor
Description
The result is intense nausea, bloating , and potentially vomiting
A 2024 study published in JAMA Ophthalmology reported that patients with Type 2 diabetes who took semaglutide-containing medications had more than a fourfold higher risk for developing non-arteritic anterior ischemic optic neuropathy (NAION) compared with patients not on a GLP-1 agonist
The honest estimate from practitioners using this approach is that roughly 60 to 70% of patients see some degree of improvement, while 30 to 40% see no meaningful change
If you wish to know more, check our complete GLP-1 healthtech market playbook
Response to letter regarding article, Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial
